Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA Approval Improvements Reveal Just How Big The Backlog Is

Executive Summary

GPhA says FDA would have to approve 150 ANDAs a month to get through its backlog; agency says it would welcome having that many approvable applications.

You may also be interested in...



ANDA Submissions Continue Yo-Yo Pattern, Unlike Approvals

After spike in March, generic drug application submissions drop 62% in April, while approval volume remains at monthly average.

ANDA Submissions Continue Yo-Yo Pattern, Unlike Approvals

After spike in March, generic drug application submissions drop 62% in April, while approval volume remains at monthly average.

FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods

Office of Generic Drugs reviewed more than 90% of official GDUFA backlog of pending applications, but many still will require more work.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS057189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel